Asthma and COPD Section
-
GOLD 2026 updates in global strategy for diagnosis, management, and prevention of COPD
The GOLD 2026 report advances a contemporary model of COPD as a modifiable, biologically active disease requiring individualized and proactive management.
-
The emerging role of biologic therapy in asthma-COPD overlap
Biologics such as dupilumab, mepolizumab, benralizumab, and tezepelumab are an emerging option for select patients with asthma-COPD overlap, particularly those with T2-high inflammatory phenotypes.
-
Expanding treatments for COPD management
Recent FDA approval of dupilumab and ensifentrine marks significant progress in therapies targeting inflammation, lung function, and symptom relief for patients with COPD.
-
Expanding recommendations for RSV vaccination
Respiratory syncytial virus (RSV) has been increasingly recognized as a prevalent cause of lower respiratory tract infection (LRTI) among adults in the United States. The risk of hospitalization and mortality from RSV-associated respiratory failure is higher in those with chronic lung disease. In adults aged 65 years or older, RSV has shown to cause up…
-
Emerging role of biologics in COPD: A new direction
Remodeling of airways and destruction of parenchyma by immune and inflammatory mechanisms are the leading cause of lung function decline in patients with COPD. Type 2 inflammation has been recognized as an important phenotypic pathway in asthma. However, its role in COPD has been much less clear, which had been largely associated with innate immune…
